CRDL
Cardiol Therapeutics Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$145M
5Y Perf.-35.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CRDL vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
CRDL vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CRDL | IMVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $145M | $5.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-32M | $-464M |
| Total Debt | $159K | $98K |
| Cash & Equiv. | $31M | $714M |
CRDL vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRDL
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cardiol Therapeutic… (CRDL) | 100 | 64.4 | -35.6% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRDL vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRDL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Immunovant, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CRDL
Cardiol Therapeutics Inc.
The Income Pick
CRDL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.24
- EPS growth -15.9%
- Lower volatility, beta 1.24, Low D/E 0.6%, current ratio 4.52x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs CRDL's -65.3%
- +96.1% vs CRDL's +20.4%
- -44.1% ROA vs CRDL's -249.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRDL | -0.2% revenue growth vs IMVT's -21.3% |
| Quality / Margins | CRDL | 3.7% margin vs IMVT's 3.2% |
| Stability / Safety | CRDL | Beta 1.24 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +96.1% vs CRDL's +20.4% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs CRDL's -249.4% |
CRDL vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRDLLAGGINGIMVT
IMVTImmunovant, Inc.
1leads
CRDLCardiol Therapeutics …
1leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRDL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRDL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CRDL and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$33M | -$487M |
| Net IncomeAfter-tax profit | -$32M | -$464M |
| Free Cash FlowCash after capex | -$24M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +19.7% |
CRDL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CRDL and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $145M | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $123M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.48x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 5.13x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CRDL and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-3 for CRDL. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRDL's 0.01x.
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -3.4% | -47.1% |
| ROA (TTM)Return on assets | -2.5% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -151.2% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x |
| Net DebtTotal debt minus cash | -$30M | -$714M |
| Cash & Equiv.Liquid assets | $31M | $714M |
| Total DebtShort + long-term debt | $158,532 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — CRDL and IMVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $4,851 for CRDL. Over the past 12 months, IMVT leads with a +96.1% total return vs CRDL's +20.4%. The 3-year compound annual growth rate (CAGR) favors CRDL at 31.6% vs IMVT's 12.1% — a key indicator of consistent wealth creation.
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +30.8% | +5.1% |
| 1-Year ReturnPast 12 months | +20.4% | +96.1% |
| 3-Year ReturnCumulative with dividends | +127.9% | +40.9% |
| 5-Year ReturnCumulative with dividends | -51.5% | +62.4% |
| 10-Year ReturnCumulative with dividends | -65.3% | +173.6% |
| CAGR (3Y)Annualised 3-year return | +31.6% | +12.1% |
Evenly matched — CRDL and IMVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CRDL and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CRDL is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs CRDL's 76.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.37x |
| 52-Week HighHighest price in past year | $1.71 | $30.09 |
| 52-Week LowLowest price in past year | $0.88 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +76.0% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 746K | 1.4M |
Evenly matched — CRDL and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CRDL as "Buy" and IMVT as "Buy". Consensus price targets imply 515.4% upside for CRDL (target: $8) vs 67.2% for IMVT (target: $46).
| Metric | CRDLCardiol Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $45.50 |
| # AnalystsCovering analysts | 2 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRDL leads in 1 of 6 categories (Income & Cash Flow). IMVT leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallCardiol Therapeutics Inc. (CRDL)Leads 1 of 6 categories
Loading custom metrics...
CRDL vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CRDL or IMVT a better buy right now?
Analysts rate Cardiol Therapeutics Inc.
(CRDL) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRDL or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -51. 5% for Cardiol Therapeutics Inc. (CRDL). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus CRDL's -65. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRDL or IMVT?
By beta (market sensitivity over 5 years), Cardiol Therapeutics Inc.
(CRDL) is the lower-risk stock at 1. 24β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 11% more volatile than CRDL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 1% for Cardiol Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRDL or IMVT?
On earnings-per-share growth, the picture is similar: Cardiol Therapeutics Inc.
grew EPS -15. 9% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRDL or IMVT?
Cardiol Therapeutics Inc.
(CRDL) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRDL leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — CRDL leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CRDL or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CRDL or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Both have compounded well over 10 years (IMVT: +173. 6%, CRDL: -65. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRDL and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.